Browse Conditions Browse Medicines

NICE publish updated guidance for chronic obstructive pulmonary disease in over 16s

For Chronic obstructive pulmonary disease (COPD)

The National Institute for Health and Care Excellence (NICE) have published updated guidance on the diagnosis and management of chronic obstructive pulmonary disease in patients aged over 16.

The guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD (which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer.

Who is it for?
People with COPD and their families and carers
Healthcare professionals
Commissioners and providers

In July 2019, NICE reviewed the evidence and made new recommendations on:
  • inhaled triple therapy for stable COPD
  • systemic corticosteroids for managing exacerbations
These supplement the existing recommendations on:
  • diagnosing COPD using symptoms, spirometry and other tests
  • managing stable COPD using nebulisers, oral therapy and pulmonary rehabilitation
  • multidisciplinary management of stable COPD, including physiotherapy, occupational therapy, nutrition and palliative care
  • managing exacerbations of COPD in primary care and in hospital

© NICE [2019]

Chronic obstructive pulmonary disease in over 16s: diagnosis and management. NICE guideline [NG115]. Published date: December 2018 Last updated: July 2019
Available from: See Link below. All rights reserved. Subject to Notice of rights
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

The information provided by NICE was accurate at the time this article was issued.

NICE guidance: Chronic obstructive pulmonary disease in over 16s: diagnosis and management

Reporting of suspected adverse reactions

Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.

About condition